文献速递肝肾功能剂量调整治疗药物监测与药物基因组学特殊人群用药

中国血液恶性肿瘤患儿万古霉素群体药代动力学研究

Population Pharmacokinetic Study of Vancomycin in Chinese Pediatric Patients with Hematological Malignancies.
PubMed 文献 · Pharmacotherapy · 2020-11-18

该回顾性研究纳入92例接受万古霉素治疗并开展治疗药物监测的中国血液恶性肿瘤患儿,采用非线性混合效应模型建立群体药代动力学模型。最终模型为一室模型,实际体重和肾小球滤过率为清除率的显著影响因素,并基于模型模拟了达到目标治疗浓度所需的剂量。

要点

  • 实际体重和肾小球滤过率是万古霉素清除率的显著影响因素。
  • 最终模型清除率公式含肾小球滤过率和体重项,表观分布容积为22.3 L。
  • 基于最终模型提出了参考给药方案,供临床参考。

核心结论

  • 采用非线性混合效应模型建立了中国血液恶性肿瘤患儿的万古霉素群体药代动力学模型,为临床用药提供参考。

主要发现

  • 一室模型加一阶消除对浓度数据拟合最佳。
  • 实际体重和肾小球滤过率是万古霉素清除率的显著影响因素。
  • 最终模型清除率公式为CL (L/h) = 4.18 × (GFR/145)^0.741 × (BW/25)^K,其中K = (BW^-0.856)/(BW^-0.856 + 6.53^-0.856),表观分布容积为22.3 L。
  • 模型稳健可靠,并基于最终模型提出了参考给药方案。

关键数值与推荐

  • 最终模型清除率公式为CL (L/h) = 4.18 × (GFR/145)^0.741 × (BW/25)^K,K = (BW^-0.856)/(BW^-0.856 + 6.53^-0.856),表观分布容积为22.3 L。
  • 基于最终模型提出了参考给药方案。

临床怎么用

  • 临床可参考基于实际体重和肾小球滤过率建立的群体药代动力学模型及据此提出的参考给药方案,优化血液恶性肿瘤患儿的万古霉素剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY OBJECTIVES: Vancomycin is a primary antibiotic for the treatment of severe infections in children with malignant hematological disease. However, precise dosing of vancomycin is difficult in children because of high interindividual variability and limited data of pharmacokinetic profiles. The present study aims to develop a population pharmacokinetic (PPK) model for vancomycin in Chinese pediatric patients with hematological malignancies. DESIGN: This was a retrospective pharmacokinetic study. SETTING: The setting for this study was a tertiary-care children's hospital. PATIENTS: This study included 92 pediatric patients with hematological malignancies who received vancomycin and experienced therapeutic drug monitoring from February 2017 to December 2018. MEASUREMENTS AND MAIN RESULTS: A PPK model was generated with a nonlinear mixed effects model. In addition, required doses to achieve target therapeutic concentrations were simulated based on the final model. A one-compartment model with first-order elimination fit the concentration data best. Actual body weight (BW) and glomerular filtration rate (GFR) were the significant influential factors on the clearance (CL) of vancomycin. The final PPK model for CL was CL (L/h) = 4.18 ×GFR/1450.741×BW/25K , K = BW-0.856/BW-0.856+6.53-0.856 , and the volume of distribution was 22.3 L. The model proved to be robust and reliable. Reference dosing regimens were proposed based on the final model. CONCLUSIONS: A PPK model of vancomycin was established for Chinese pediatric patients with hematological malignancies using a nonlinear mixed effects model, which provided a reference for the clinical application of vancomycin.

来源:Pharmacotherapy,查看原文。版权归原作者所有。

引用

  1. Wang H, Huang L, Wang J, et al. Population Pharmacokinetic Study of Vancomycin in Chinese Pediatric Patients with Hematological Malignancies. Pharmacotherapy. 2020. PMID: 33070357. doi:10.1002/phar.2473

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。